Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
SSE:603392.SS
64.14 (CNY) • At close June 17, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,245.403 | 5,476.872 | 11,185.189 | 5,750.329 | 2,354.257 | 1,183.754 | 982.687 | 949.525 | 844.082 | 680.714 | 596.234 | 499.061 |
| Cost of Revenue
| 759.045 | 1,002.384 | 1,170.412 | 817.711 | 442.142 | 330.864 | 269.084 | 281.191 | 230.176 | 174.755 | 142.025 | 116.661 |
| Gross Profit
| 1,486.359 | 4,474.488 | 10,014.777 | 4,932.618 | 1,912.115 | 852.89 | 713.602 | 668.333 | 613.906 | 505.959 | 454.208 | 382.4 |
| Gross Profit Ratio
| 0.662 | 0.817 | 0.895 | 0.858 | 0.812 | 0.72 | 0.726 | 0.704 | 0.727 | 0.743 | 0.762 | 0.766 |
| Reseach & Development Expenses
| 886.052 | 1,197.93 | 1,099.03 | 681.823 | 314.332 | 165.98 | 138.339 | 158.818 | 130.098 | 109.466 | 97.373 | 76.007 |
| General & Administrative Expenses
| 67.322 | 102.01 | 42.58 | 37.523 | 23.936 | 23.485 | 27.845 | 26.148 | 96.68 | 77.444 | 152.631 | 118.416 |
| Selling & Marketing Expenses
| 390.203 | 1,518.124 | 3,253.948 | 1,690.473 | 690.944 | 333.392 | 265.743 | 266.083 | 251.992 | 191.164 | 171.248 | 151.069 |
| SG&A
| 457.525 | 1,936.102 | 3,296.528 | 1,727.996 | 714.88 | 356.877 | 293.588 | 292.231 | 348.672 | 268.608 | 323.879 | 269.485 |
| Other Expenses
| 48.944 | -27.085 | 19.638 | 86.422 | 57.166 | 108.74 | 1.163 | -0.193 | 21.318 | 9.361 | 19.11 | 6.997 |
| Operating Expenses
| 1,392.521 | 3,236.089 | 4,415.195 | 2,496.24 | 1,086.379 | 631.596 | 541.705 | 478.051 | 483.555 | 381.162 | 326.994 | 272.749 |
| Operating Income
| 93.838 | 1,401.451 | 5,596.038 | 2,328.456 | 775.203 | 218.33 | 289.123 | 178.743 | 131.439 | 121.841 | 115.238 | 96.231 |
| Operating Income Ratio
| 0.042 | 0.256 | 0.5 | 0.405 | 0.329 | 0.184 | 0.294 | 0.188 | 0.156 | 0.179 | 0.193 | 0.193 |
| Total Other Income Expenses Net
| -26.357 | -8.059 | -13.347 | -4.31 | -10.751 | -1.522 | 1.163 | -0.193 | 21.266 | 9.269 | 19.05 | 6.974 |
| Income Before Tax
| 67.481 | 1,393.392 | 5,582.691 | 2,324.145 | 764.452 | 216.808 | 290.287 | 178.551 | 152.705 | 131.109 | 134.288 | 103.205 |
| Income Before Tax Ratio
| 0.03 | 0.254 | 0.499 | 0.404 | 0.325 | 0.183 | 0.295 | 0.188 | 0.181 | 0.193 | 0.225 | 0.207 |
| Income Tax Expense
| -41.614 | 146.887 | 719.39 | 244.931 | 82.636 | 6.506 | -2.589 | 28.192 | 21.227 | 24.618 | 15.828 | 23.345 |
| Net Income
| 106.235 | 1,247.68 | 4,735.795 | 2,021.468 | 676.997 | 208.864 | 293.068 | 150.407 | 148.189 | 119.361 | 118.46 | 79.826 |
| Net Income Ratio
| 0.047 | 0.228 | 0.423 | 0.352 | 0.288 | 0.176 | 0.298 | 0.158 | 0.176 | 0.175 | 0.199 | 0.16 |
| EPS
| 0.08 | 0.99 | 3.79 | 1.64 | 0.57 | 0.19 | 0.27 | 0.15 | 0.14 | 0.12 | 0.12 | 0.081 |
| EPS Diluted
| 0.08 | 0.99 | 3.79 | 1.64 | 0.57 | 0.19 | 0.27 | 0.15 | 0.14 | 0.12 | 0.12 | 0.081 |
| EBITDA
| 376.457 | 1,657.02 | 5,742.261 | 2,435.112 | 850.605 | 293.541 | 357.443 | 214.786 | 152.258 | 132.279 | 132.329 | 109.651 |
| EBITDA Ratio
| 0.168 | 0.303 | 0.513 | 0.423 | 0.361 | 0.248 | 0.364 | 0.226 | 0.18 | 0.194 | 0.222 | 0.22 |